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ABSTRACT
BNP (B-type natriuretic peptide) has been reported to be elevated in preclinical states of vascular
damage. To elucidate the relationship between plasma BNP and endothelial function, we have
investigated the relationship between BNP and endothelial function in a cohort of subjects
comprising healthy subjects as well as at-risk subjects with cardiovascular risk factors. To also
clarify the relative contribution of different biological pathways to the individual variation in
endothelial function, we have examined the relationship between a panel of multiple biomarkers
andendothelialfunction.Atotalof70subjectswerestudied(meanage,58.1+ −4.6 years;27%hada
history of hypertension and 18% had a history of hypercholesterolaemia). Endothelium-dependent
vasodilatation was evaluated by the invasive ACH (acetylcholine)-induced forearm vasodilatation
technique. A panel of biomarkers of biological pathways was measured: BNP, haemostatic factors
PAI-1 (plasminogen-activator inhibitor 1) and tPA (tissue plasminogen activator), inﬂammatory
markers, including cytokines [hs-CRP (high sensitive C-reactive protein), IL (interleukin)-6, IL-
8, IL-18, TNFα (tumour necrosis factor α) and MPO (myeloperoxidase] and soluble adhesion
molecules [E-selectin and sCD40 (soluble CD40)]. The median BNP level in the study population
was 26.9 pg/ml. Multivariate regression analyses show that age, the total cholesterol/HDL (high-
density lipoprotein) ratio, glucose and BNP were independent predictors of endothelial function,
and BNP remained an independent predictor (P=0.009) in a binary logistic regression analysis
using FBF (forearm blood ﬂow) as a dichotomous variable based on the median value. None
of the other plasma biomarkers was independently related to ACH-mediated vasodilatation. In
a strategy using several biomarkers to relate to endothelial function, plasma BNP was found
to be an independent predictor of endothelial function as assessed by endothelium-dependent
vasodilatation in response to ACH.
INTRODUCTION
BNP (B-type natriuretic peptide) possesses comple-
mentary functions in regulating BV (blood volume)
and vascular smooth muscle tone and is vital to the
maintenance of cardiovascular homoeostasis [1]. The
physiological actions of BNP include the regulation
of vascular tone by activation of the particulate
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isoform of guanyl cyclase after binding to natriuretic
peptidereceptorAandbydirectendothelium-dependent
nitric oxide production [2,3]. An inverse relationship
between plasma BNP level and endothelial function has
been reported in patients with CVD (cardiovascular
disease), including patients with heart failure [4–7].
These observations have led to the speculation that
BNP can serve as a biomarker of preclinical CVD,
including endothelial dysfunction [8]. However, an
inverse relationship between plasma natriuretic peptides
andendothelialfunctionhasnotbeenaconsistentﬁnding
[5].
To further elucidate the relationship between plasma
BNP and endothelial function at an early stage, we have
investigated whether BNP is related to resistance vessel
endothelial function, assessed by FBF (forearm blood
ﬂow) responses to brachial artery infusions of ACH
(acetylcholine) [7] in a group of healthy subjects as well
as at-risk individuals with cardiovascular risk factors.
As endothelial function is also inﬂuenced by several
otherbiologicalpathwayssuchashaemostaticfactorsand
inﬂammation [9], we have also examined the relationship
betweenendothelialfunctionandapanelofbiomarkersof
haemostasis and inﬂammation in our cohort of subjects.
MATERIALS AND METHODS
Study population
Our study subjects were recruited from the control
arm of an on-going Wellcome Trust United Kingdom
Case Control Collection for Type 2 diabetes study
based in Dundee. Consequently, none of the subjects
had a diagnosis of diabetes mellitus, but subjects with
an IFG (impaired fasting glucose) were included [10].
Subjects varied in terms of cardiovascular risk proﬁle and
rangedfromzerotomultipleconventionalriskfactorsfor
atherosclerosis. Subjects with a history of atherosclerotic
disease (coronary artery disease, cerebrovascular disease
and peripheral vascular disease) were excluded. All
participants gave their written informed consent to
participate in this study which was approved by the
TaysideCommitteeonMedicalEthics.Theinvestigations
conformed to the principles outlined in the 2008
Declaration of Helsinki.
A detailed medical history was obtained and cardio-
vascular risk factors were recorded and included age,
smoking history, history of hypertension, hypercholes-
terolaemia and renal dysfunction. Smoking was deﬁned
as current smokers and non-smokers. Current smokers
were those who smoked within the previous month.
The use of regular medication was also recorded. All
subjects underwent physical examination and included
measurement of BP (blood pressure), weight and height
for determination of BMI (body mass index).
Blood sampling and analysis
Participants attended a temperature-controlled laborat-
ory(24–26◦C)inourresearchunitafteranovernightfast,
having refrained from tea, coffee or tobacco for 12 h. All
participants had a resting ECG (Eclipse 850; Spacelabs
Burdick). BP was measured in the non-dominant arm
after at least 30 min of rest. The average of three
recordings was used.
All participants rested for at least 30 min before
venipuncture. Blood was collected through an 18-guage
cannula inserted in the anticubital fossa. The tourniquet
wasremovedandbloodwasallowedtoﬂowfreely.Blood
(75 ml) was drawn into blood bottles containing citrate
[tPA (tissue plasminogen activator)], heparin [E-selectin,
ICAM-1 (intercellular adhesion molecule-1) and MPO
(myeloperoxidase)], EDTA [sCD40 (soluble CD40),
BNP and hs-CRP (high-sensitive C-reactive protein)],
CTAD (citrate/theophylline/adenosine/dipyridamole)
tubes (BectonDickinson) for PAI-1 (plasminogen-
activator inhibitor-1) assay. Serum samples were used for
TNFα (tumour necrosis factor α) and ILs (interleukins;
IL-6, IL-8 and IL-18). Blood was also collected in
vacutainer tubes for measurement of HbA1c (glycated
haemoglobin), serum lipids and glucose.
Serum tubes were immediately transferred to a water
bath at 37◦C. Citrate, heparin, BNP, EDTA and CTAD
tubeswerespunat1500 gfor15 minat4◦C.Aftertheﬁrst
spin, citrate, heparin and EDTA tubes were transferred
to an ice bucket and the supernatant aliquoted in 1.5 ml
tubes and stored at −80◦C. Serum specimens, EDTA
and CTAD were spun for a further 15 min at 1500 g at
4◦C. The supernatants were stored in small aliquots at
−80◦C.
hs-CRP, TNFα, IL-6, IL-8, IL-18, BNP, E-
selectin, ICAM-1, sCD40 and MPO were analysed
with commercially available kits by the technique of
quantitative enzyme immunoassay technique using a
speciﬁc monoclonal antibody on a microplate. PAI-1 and
tPA were measured by quantitative ELISA [11,12]. The
inter- and intra-assay coefﬁcients of variability for these
assays in our laboratory are as follows: hs-CRP, 16.2 and
8.5%; TNFα, 7.3 and 3.1%; IL-6, 6.5 and 6.9%; IL-8,
5.4 and 6.1%; IL-18, 5.2 and 5.3%; BNP, 2 and 14%;
E-selectin, 7.3 and 5.2%; ICAM-1, 4.4 and 3.6%); and
sCD40, 6.0% and 4.5%.
FBF
Subjects underwent cannulation of the non-dominant
brachial artery under local anaesthesia with a 27-gauge
steel needle (Coopers Needleworks) mounted on to a
16-gauge epidural catheter (Portex). Physiological saline
was infused (Graseby 3100 syringe pump) at a constant
rate of 1 ml/min in the ﬁrst 30 min to allow resting
blood ﬂow to stabilize. Baseline FBF was measured by
means of forearm venous occlusion plethysmography
as described previously [13]. When resting ﬂows were
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established, FBF was measured during the last 2 min
of 5-min drug infusions. Drugs infused were ACH (50
and 100 nmol/min; Novartis) and sodium nitroprusside
(37.8 nmol/min; Mayne Pharma). Each drug infusion
period was separated by a washout period (10–30 min)
with 0.9% saline to allow ﬂows to normalize. FBF was
expressed as the percentage change in the ratio of infused
to the non-infused arm calculated according the method
described by Whitney [14]. BP was measured in the
non-infused arm before each infusion period and at the
conclusion of the study. Forearm vascular resistance was
calculated by taking the ratio of MAP (mean arterial
pressure) and the FBF value in units of mmHg/ml per
100 ml per min.
All procedures and data analysis were performed by a
single researcher to eliminate inter-observer variability.
Statistical analysis
We tested the distribution of continuous variables
by visual inspection of the frequency histogram and
Shapiro–Wilk test. For non-normally distributed data, a
logarithmic transformation was used to achieve a normal
distribution. Normally distributed data are presented as
means+ −S.D., whereas non-normally distributed data are
given as medians (interquartile range).
To determine predictors of endothelial function, a
univariate and stepwise multivariate linear regression
analysis were performed. The variables were chosen
based on previous studies and included age, sex,
smoking, SBP (systolic blood pressure), statin use, use
of ACE-Is (angiotensin-converting-enzyme inhibitors)
or ARBs (angiotensin II type 1 receptor blockers),
BMI, the total cholesterol/HDL ratio and the plasma
biomarkers described. All biomarker measurements
(including glucose) were treated as continuous variable.
Predictors with a P< 0.1 on the univariate analysis were
entered into a stepwise multivariate linear regression.
The accuracy of the model was determined using the R-
value. Assumptions for general linear models were tested
including testing of residuals for normal distribution and
Durbin–Watson test to detect autocorrelation.
Using median FBF as a dichotomous variable, a
logistic regression analysis was carried out to determine
whether BNP remained an independent predictor of
endothelial function. To further examine the incremental
effect of BNP on the conventional factors including
age, gender, SBP, smoking, the total cholesterol/HDL
ratio and glucose, the c-statistic using ROC (receiver
operatorcharacteristic)curveanalysiswasused.Alogistic
regression model was prepared, and the area under
the ROC curve was compared between conventional
factors and conventional factors and BNP. The Hosmer–
Lemeshow goodness-of-ﬁt test was used to assess the
logistic model ﬁt. All probability values are presented
as two-tailed, with statistical signiﬁcance inferred at P<
0.05. All statistical analyses were performed using SPSS
Table 1 Clinical characteristics of study subjects
Values are expressed as means+ −S.D. or medians (interquartile range).
Cardiovascular risk factors were hypercholesterolaemia, hypertension, current
smoker and impaired fasting glucose. HbA1c, glycated haemoglobin; HMG-CoA,
3-hydroxy-3-methylglutaryl-CoA; HR, heart rate.
Variable Value
Clinical characteristics
Age (years) 58.1+ −4.6
Sex (male) 94.3%
Hypertension 27%
Hypercholesterolaemia 18%
Smoking status (within previous month) 15.7%
HR (beats/min) 59.1+ −7.3
SBP (mmHg) 136.5+ −14.4
Diastolic blood pressure (mmHg) 78.0+ −8.6
BMI (kg/m2) 28.5+ −4.2
Total cholesterol/HDL ratio 3.9+ −1.03
Glucose (mmol/l) 5.40 (1.0)
HbA1c (%) 5.50 (1.0)
Cardiovascular risk factors (n)
02 1 ( 3 0 % )
12 9 ( 4 1 % )
21 5 ( 2 1 % )
At least 3 5 (7%)
Medication (%)
Aspirin 7.1
HMG-CoA reductase inhibitors 18.6
ACE-I/ARB 14.3
Calcium channel blockers 12.9
Bendroﬂumethiazide 7.1
β-Blockers 5.7
forWindowsversion17.0.ROCcurvesweretestedusing
Excel spreadsheet.
RESULTS
Subject characteristics, biomarkers and
vascular function measures
Attotalof70subjectsparticipatedinthisstudy.Themean
age was 58.1+ −4.6 years with a predominance of males in
our study. Table 1 shows the clinical characteristics of the
subjects. Of these, 19 (27%) subjects reported a history
of hypertension and were all on medication [ten (14%)
on ACE-Is or ARBs, nine (12.9%) on CCBs (calcium
channel blockers) and ﬁve (7.1%) on thiazide diuretics].
Then 18% had a history of hypercholesterolaemia and
all were on a statin and ﬁve (7.1%) were on an aspirin
(prescribed for primary prevention). Then 34 (48.6%)
had impaired fasting blood glucose.
Serum and plasma levels of the biomarkers of subjects
are shown in Table 2. The median plasma BNP level was
26.9 (interquartile range, 18.1–59.3) pg/ml.
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Table 2 Plasma biomarker levels and FBF of the study
subjects
Values are medians (interquartile range)
Biomarker Value
hs-CRP 0.78 (0.35–1.80)
TNFα (pg/ml) 2.15 (1.59–3.49)
IL-6 (pg/ml) 1.28 (0.90–1.79)
IL-8 (pg/ml) 14.4 (8.9–21.7)
IL-18 (pg/ml) 289.5 (203.1–364.1)
PAI-1 (ng/ml) 34.4 (21.1–46.4)
BNP (pg/ml) 26.9 (18.1–59.3)
tPA (ng/ml) 9.1 (6.68–10.88)
ICAM-1 (ng/ml) 242.2 (212.3–286.5)
E-selectin (ng/ml) 47.3 (38.3–58.3)
sCD40 (pg/ml) 72.3 (46.5–112.0)
MPO (ng/ml) 167.8 (81.9-229.2)
Figure 1 FBF response in subjects without and with
conventional risk factors for coronary artery disease
The mean hs-CRP in the present study was 0.78
and ranged from 0.1 to 4.5, reﬂecting volunteers with
a spectrum of cardiovascular risk proﬁle.
FBF responses to ACH at 50 and 100 nmol/min
were signiﬁcantly lower in at-risk subjects when
compared with healthy subjects at both doses (P
0.01) (Figure 1). There was no difference endothelial
independent vasodilatation between healthy subjects and
at-risk subjects with cardiovascular risk factors.
Univariate and multivariate linear
regression analysis
In the univariate model, age, BMI, SBP, the total
cholesterol/HDL ratio, glucose, log BNP and log MPO
Figure 2 ROC curve for conventional risk factors with and
without BNP for predicting FBF
reached the pre-speciﬁed P<0.1 criteria to be entered
into the model. In the multivariate analysis only age,
the total cholesterol/HDL ratio, glucose and log BNP
were independent predictors of FBF. The overall R
value of the model was 0.63 (P=0.049) with BNP and
0.60 (P=0.03) without BNP. There were no co-linearity
(r>0.9) between the predictors and the residuals were
normally distributed.
BNP (log-transformed) remained an independent
predictor (P=0.009) in a binary logistic regression
analysisusingFBFasadichotomousvariablebasedonthe
median value together with age (P=0.031) and the total
cholesterol/HDL ratio (P=0.028), although glucose was
non-signiﬁcant in this model.
The area under the ROC curve for conventional risk
(age, SBP, glucose and the total cholesterol/HDL ratio)
factors was 0.75 [95% CI (conﬁdence interval), 0.63–
0.87;(P< 0.001]and0.82(95%CI,0.72–0.92;P< 0.001)
for conventional risk factors and BNP (Figure 2). The
difference between the two ROC curves was, however,
not statistically signiﬁcant. In our study, BNP was not
associated with forearm vascular resistance.
DISCUSSION
Our study has two main ﬁndings. First, in a cohort of
individualswithoutovertcoronaryarterydisease,plasma
BNP together with the established cardiovascular risk
factors of age, glucose and the total cholesterol/HDL
ratio correlated inversely with endothelial function
as assessed by the invasive ACH-induced forearm
vasodilationtechnique. Secondly, noneof thebiomarkers
related to haemostasis and inﬂammation was found to
be related to endothelial function.
Chong et al. [4] ﬁrst reported an inverse correlation
betweenFMD(ﬂow-mediateddilatation)andBNPlevels
in patients with heart failure. Elevated levels of BNP
predict abnormal coronary endothelial function [6] and
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the burden of coronary atherosclerosis determined by
electron-beam CT (computed tomography) [15]. The
ﬁndings of the current study add to evidence that
BNP may serve as a plasma biomarker of endothelial
dysfunction.
However, it should be noted that the ﬁndings of the
present study differ from the results of some previous
studies. In the Framingham study, BNP was related
to FMD, another measure of endothelial function [16]
[and a positive rather than an inverse relationship was
reported between plasma N-terminal pro-ANP (atrial
natriuretic peptide) and FMD] [5]. An analysis of the
PIVUS (Prospective Investigation of the Vasculature in
Uppsala Seniors) studyshowed that BNP was not related
to endothelial function assessed both by FMD and by the
intra-brachialACHinfusionmethod[17].Thereasonfor
discrepancy between these ﬁndings and our study is not
clear.Onepossibilityisthat,intheFraminghamstudy,the
plasma natriuretic peptides were measured on an average
of2.9 yearsbeforethevascularmeasures.Therewerealso
measurement-related problems in the Framingham study
with undetectable BNP levels reported in 25–40% of the
subjects. The PIVUS study was a study of Caucasians
aged 70 years. This striking difference in age between
study samples may explain the difference in ﬁndings.
In our present study, we did not ﬁnd any relationship
between endothelial function and plasma biomarkers of
inﬂammation. Although there have been studies that
havereportedaninverserelationshipbetweenendothelial
function and inﬂammatory markers, including hs-CRP
[18–20], this is not a universal ﬁnding [21,22]. The
manner in which endothelial function is assessed may
be important. Lind et al. [23] recently reported that
ACH-induced vasodilatation in the forearm, but not
FMD, was inversely related to hs-CRP levels and E-
selectin independently of traditional risk factors in
elderlysubjects.Thusinﬂammationevaluatedbyhs-CRP
levels could have different inﬂuences on endothelium-
dependent vasodilatation in resistance vessels evaluated
by ACH stimulation as opposed to conductance vessels
evaluated by FMD in the brachial artery.
What are the potential mechanisms linking endothelial
dysfunction and a raised BNP? One possible explanation
is that endothelial dysfunction tracks arterial stiffness,
a measure of the viscoelastic properties of arteries and
hence afterload [24]. We previously showed in patients
with diabetes that BNP increases as the augmentation
index increases [25], although it is recognized that the
augmentation index may be inﬂuenced by factors other
than arterial stiffness, such as HR (heart rate), height and
ejection duration [26]. Nevertheless, our previous study
would suggest that stiff arteries/arterioles could increase
afterload and subtly increase intra-cardiac pressure and
thus BNP. BNP levels were, however, not related
to endothelial-independent vasodilatation. Another
possible explanation is that endothelial dysfunction may
beasignofearlyatherosclerosisinawidevarietyofblood
vessels, including the coronary vessels. In turn, coronary
atherosclerosis could produce myocardial ischaemia. In
fact, myocardial tissue that is injured in any way, such as
by ischaemia, appears to express and release more BNP
than non-injured or non-ischaemic myocardial tissue,
irrespective of haemodynamic considerations [27,28].
Thus endothelial dysfunction could imply subtle but
asymptomatic myocardial ischaemia that is identiﬁable
byasubtlyelevatedNPlevel.Infact,werecentlyshowed
that subtle elevations in BNP are indicative of silent
myocardial ischaemia in Type 2 diabetics [28].
Although BNP was an independent predictor of
endothelialfunction,itdoesnotseemtohaveincremental
value over the traditional risk factors (age, BMI, BP and
glucose) as assessed by the area under the ROC curve in
our study.
Limitations
We have carried out an observational study and thus
the design of our study does not allow conclusions on
possible causal relationships observed and further studies
are warranted.
Conclusions
In a strategy using several biomarkers to relate to
endothelial function assessed by the invasive ACH-
induced forearm vasodilatation technique, plasma BNP
was found to be an independent predictor of endothelial
function.
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